Going to Cambridge

“Kymab always saw that China was a big opportunity, but we didn’t know how best to realise it”


Six year-old Kymab has just received $100 million in investment from Shenzhen Hepalink and the Hong Kong-based ORI Healthcare Fund. Kymab’s boss Dave Chiswell says the UK-based biotech firm has raised a total of $220 million in total from the likes of the Bill & Melinda Gates Foundation and said “it’s been quite a long courtship in China”. The Cambridge company specialises in cutting edge antibody customisation and its treatments show great potential in fields like fighting cancer.

© ChinTell Ltd. All rights reserved.

Sponsored by HSBC.

The Week in China website and the weekly magazine publications are owned and maintained by ChinTell Limited, Hong Kong. Neither HSBC nor any member of the HSBC group of companies ("HSBC") endorses the contents and/or is involved in selecting, creating or editing the contents of the Week in China website or the Week in China magazine. The views expressed in these publications are solely the views of ChinTell Limited and do not necessarily reflect the views or investment ideas of HSBC. No responsibility will therefore be assumed by HSBC for the contents of these publications or for the errors or omissions therein.